Zejula® (niraparib) – Expanded indication
On October 23, 2019 - GlaxoSmithKline announced the FDA approval of Zejula (niraparib), for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer in certain patients.
Download PDF
